Catherine Pellat-Deceunynck

8PUBLICATIONS
27CO-AUTHORS
Haematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)BiomaterialsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 19, 2026
CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival.

Candice Madiot, Céline Bellanger, Christelle Dousset

|Oct 09, 2024
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.

Romane Durand, Céline Bellanger, Géraldine Descamps

|Sep 11, 2024
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret

|Mar 06, 2024
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.

C Grandclément, C Estoppey, E Dheilly

|Dec 14, 2023
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.

Romane Durand, Géraldine Descamps, Céline Bellanger

|Aug 10, 2023
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.

Salomé Decombis, Celine Bellanger, Yannick Le Bris

Pageof 2

Frequent Collaborators

5 joint publications

David Chiron

3 joint publications

Géraldine Descamps

3 joint publications

Patricia Gomez-Bougie

3 joint publications

Yannick Le Bris